Mission and vision
The RAS Initiative Europe will constitute a network of collaborating European scientists dedicated to developing new rational therapeutic approaches for the approximately 30% of human cancers driven by mutations in one of the RAS genes. This European effort is endorsed by, coordinated with, and complementary to the US based RAS Initiative at the NIH NCI.
Its complementary nature will arise from the emphasis of the European network on promoting academic clinical trials as a key source of clinical information, patient derived material, and novel hypotheses that can feed and strengthen preclinical research across the continent.
Towards a Legal Framework
and Initial Funding
Preliminary consultations within a working group of European RAS scientists have identified the creation of a Scientific Society as the most appropriate administrative framework for this future network.
We are currently contacting national cancer research associations to inform them of this initiative and to explore opportunities for securing the initial economic support required before the Society becomes a fully functional entity.
A Strategic Hub for
RAS Innovation
Given the profound scientific, societal, and clinical impact of RAS driven cancers, this framework is designed to become a permanent hub for interaction between clinical and basic researchers, funding bodies, patient associations, and policymakers.
By joining this initiative, cancer research associations will play a pivotal role in shaping a coordinated, continent wide effort to accelerate breakthroughs in RAS targeted therapies and improve outcomes for patients.